A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day &amp; 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study

Sharma, Saurabh; Hiran, K. R.; Pavithran, Keechilat; Vijaykumar, D K

doi:10.1186/1477-7819-7-35

Cited by 7 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous studies, the immunohistochemical (IHC) expression pattern and intensity of different biomarkers may be altered after chemotherapy. [11][12][13][14][15][16] On the basis of these findings, breast cancer epithelial markers, such as CK19, might undergo similar changes, and consequently CK19 should not be used as a target to search for metastatic cells; however, whether these changes occur has not been evaluated until the present study.…”

Section: Introductionmentioning

confidence: 97%

CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 97%

CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Unlike ODonovan (2003) study in 103 breast tissue samples, they showed that Caspase-3 precursor and active form were higher in breast cancer than normal tissue (p=0.0188; p=0.0002) [17]. Similarly, Sharma (2009) showed that tumor biology markers (Bcl-2, Apoptotic Index and Caspase-3) changes occurred 24-48 hours after first neoadjuvant chemotherapy cycles. These markers cpuld be as a factors to predict the response of chemotherapy, but to prove them statistically, need research with a larger sample size [18].…”

Section: Discussionmentioning

confidence: 93%

Apoptotic Index Fails to Predict Chemoresponse in Breast Cancer

Siregar

2019

Sumat. Med. J.

View full text Add to dashboard Cite

The responsiveness of neoadjuvant chemotherapy in Triple Negative Breast Cancer (TNBC) needs determination to prevent overtreatment with chemoresistance regimen. A total of 60 consented patients from Haji Adam Malik and Bunda Thamrin Hospital were included in this cohort prospectie study. Patients with heart, kidney, liver disease, history of surgery, chemotherapy, or hormonal therapy were excluded. Apoptotic indexes were taken from all subjects before and after neoadjuvant chemotherapy. After 3 cycles of neoadjuvant chemotherapy, 31 subjects (51.7%) did not show clinical response while 29 subjects (48.3%) had clinical response. There was no significant difference of apoptotic index before and after neoadjuvant chemotherapy (5.47+1.38 vs 5.52+1.08 pg/mL). There was also no significant relationship between apoptosis index and clinical response (p=0.993). This study showed that apoptotic index fails to be neoadjuvant chemotherapy response predictor in triple negative breast cancer. Further research with larger samples is needed to confirm this result

show abstract

“…The greatest interest in recent years has focused on the biomarker, Ki-67, as an index of proliferative activity. Numerous previous studies have shown that Ki-67 is an independent predictive marker for a local relapse, and for overall and disease-free survival (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23). No previous studies, to the best of our knowledge, have shown lateral differences in Ki-67 in BC.…”

Section: Introductionmentioning

confidence: 80%

Lateral differences in Ki-67 in breast cancer

Dmitrenko¹

2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Morphological features of right- and left-sided breast cancer (BC) have been rarely studied. Ki-67 is an independent predictive marker for a local relapse, and for overall and disease-free survival. In previous literature, lateral differences in Ki-67 in BC have not been reported. Using immunohistochemical analysis, the biopsy material of 500 patients was investigated. Four BC parameters were investigated: The expression levels of the estrogen receptor (ER), progesterone receptor (PR), Ki-67 and Her-2-neu. A comparative analysis of Ki-67 in groups with right- and left-sided BC was performed. Lateral differences in Ki-67 in three age groups, ≤49, 50-59 and ≥60 years, were assessed. A higher expression of Ki-67 corresponded with right-sided BC (r=-0.08; P=0.046). Correlation of Ki-67 with the age of the patient was characteristic only for right-sided BC (r=-0.28; P<0.001). The comparative analysis revealed that tumors from patients with right-sided BC aged ≥60 years exhibited a lower Ki-67 index compared with tumors from patients aged ≤49 (P=0.003) and 50-59 years (P=0.000013). In left-sided BC, the Ki-67 in the different age intervals revealed no significant difference. On performing an assessment of lateral differences for the different age intervals, it was established that the Ki-67 index of right-sided BC was significantly higher compared with the left-sided BC in two of the age groups, ≤49 (P=0.038) and 50-59 years (P=0.047). In the ≥60 years group, lateral differences in Ki-67 were not revealed (P=0.4). The analysis of lateral differences in Ki-67 in tumors of various receptor profiles revealed significant differences in Ki-67 of the right- and left-sided BC under ER PR (P=0.007) and ER PR (P=0.016) conditions. The reasons behind lateral and age differences of Ki-67 are discussed.

show abstract

A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study

Cited by 7 publications

References 27 publications

CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

Apoptotic Index Fails to Predict Chemoresponse in Breast Cancer

Lateral differences in Ki-67 in breast cancer

Contact Info

Product

Resources

About